BioDuro and CTI Biotechnology in preclinical drug development partnership
pharmafile | May 21, 2026 | News story | Research and Development |Â Â BioDuro, CTI BiotechnologyÂ
BioDuro has announced a strategic partnership with CTI Biotechnology. The collaboration will leverage the complementary strengths of both companies across critical stages of preclinical R&D to establish an integrated platform spanning from drug discovery to investigational new drug (IND) submission, providing global biotech and pharmaceutical clients with more efficient and flexible development solutions.
Under the partnership, BioDuro will provide integrated capabilities including discovery chemistry, biology, drug metabolism and pharmacokinetics (DMPK) and pharmacology, as well as API and drug product development and manufacturing, together with IND filing support across global markets. CTI Biotechnology will contribute GLP toxicology studies and bioanalytical services in readiness for successful IND submission.
By combining their complementary expertise and coordinating project execution, the two companies will deliver a high-quality, one-stop discovery and development solution that helps clients streamline workflow, reduce communication and management complexity, and more efficiently advance innovative therapies.
Armin Spura, CEO of BioDuro, said: “Successful IND submission depends on strong execution across every critical step of early development, and GLP toxicology is one of the most important milestones in that journey. By combining BioDuro’s integrated discovery and development capabilities with CTI’s proven expertise in GLP toxicology and bioanalytical services, we are strengthening our ability to help clients move innovative programs forward with greater speed, confidence, and efficiency.”
Tony Liu, General Manager of CTI Biotechnology, added: “Our strategic collaboration with BioDuro will further enhance our combined service capabilities in preclinical development and provide clients worldwide with a more complete and efficient integrated solution.”
BioDuro is a global contract research, development and manufacturing organisation (CRDMO) and CTI Biotechnology provides preclinical research services for innovative drug development.
Related Content
BioDuro establishes joint manufacturing venture with Cenra
BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with …
BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery
BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
